Shamburg News · 8-K filed Nov 12, 2026, 4:07 PM EST

Obsidian Therapeutics Reports Third Quarter 2026 Financial Results

OBX · Obsidian Therapeutics, Inc.

  • Earnings
  • Materiality: high

Obsidian Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026 in a press release furnished as Exhibit 99.1. The company reported a net loss of $50.7 million, or $1.23 per basic and diluted share, and research and development expenses of $27.5 million for the three months ended September 30, 2026. Cash, cash equivalents, and marketable securities were $324.4 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458347.

Written from the filing by Shamburg Markets. Figures are as reported by the company.